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Methods: Urine was collected from 78 bladder-cancer patients
during follow-up, from 20 patients with benign urological disease,
and from 20 healthy volunteers. RNAwas isolated from exfoliated
cells in urine by use of an RNA purification kit, and real-time PCR
was performed with specific primers for the amplification of
CK20, a marker for TCC urothelium.
Findings: A strong correlation was found between tumour
grade and expression of CK20 in urine. All patients with grade
III and IV tumours showed positive CK20 expression in the exfo-
liated cells, with 100% sensitivity. The sensitivity for lower grades
was up to 83%. Out of 13 TCC patients, CK20 expression was
found in nine patients who were previously diagnosed by biopsy
and had a negative biopsy following treatment. These nine
patients were followed up for 6 months, and TCC recurred in four
patients.
Interpretation: Quantitative detection of CK20 in exfoliated cells
of urine is a simple and non-invasive method for monitoring and
follow-up of TCC in patients with bladder cancer. However, more
information is needed regarding CK20 expression in non-malig-
nant urological diseases to use it as amarker for routine screening.
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Background: Anthracycline-based neoadjuvant chemotherapy
kills cancer cells by inducing DNA double-strand breaks. In-
vitro studies have shown that DNA damage leads to localised
DNA methylation on CpG-rich sites found in promoter
regions. Promoter methylation of some tumour-suppressor
genes has been associated with poor prognosis. To determine
whether neoadjuvant chemotherapy induces promoter methyl-
ation, we evaluated the promoter regions of the SFRP1 and
CDH1 genes in locally advanced breast cancer, before and
after treatment.
Methods: Paired FFPE blocks of 61 patients with locally
advanced breast cancer before and after chemotherapy were col-
lected and confirmed by pathologists. Patients had standard fluo-
rouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC)
chemotherapy for three cycles. In a subset of 12 patients, epige-
netic therapy (hydralazine and magnesium valproate) was added.
DNA isolation and bisulfite conversion were performed to evalu-
ate promoter methylation of SFRP1 and CDH1 genes using
methyl-specific PCR (MSP).
Findings: Using SFRP1 and CDH1 as surrogate markers, 13 of 41
(32%) and 18 of 48 (38%) patients showed induction of promoter
hypermethylation after chemotherapy (p = 0.052 and p = 0.012,
McNemar test). However, the rate of demethylation of both mark-
ers was 10%. To explore the reversibility of chemotherapy-
induced promoter hypermethylation, a subset of 12 patients were
treated with a combination of epigenetic therapy and chemother-
apy. Two of 12 patients (17%) showed hypermethylation and four
of 12 (33%) had an increased rate of promoter demethylation. The
dynamic status of promoter methylation is not associated with
hormone-receptor status, HER2 expression, age, or stage.
Interpretation: Neoadjuvant chemotherapy can induce pro-
moter methylation of tumour suppressor genes in a significant
proportion of patients, which may affect long-term clinical out-
come. This trend of promoter hypermethylation of tumour-sup-
pressor genes can be reversed using epigenetic therapy.
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Background: To determine the recommended dose and dose-
limiting toxicity (DLT) of epirubicin, oxaliplatin, and S-1 (EOS)
combination in patients with previously untreated advanced gas-
tric cancer (AGC).
Methods: Previously untreated patients with histologically pro-
ven metastatic or recurrent AGC and ECOG performance status 0–
2 were enrolled. A fixed dose of epirubicin (50 mg/m2) and oxalipl-
atin (130 mg/m2) was administered intravenously on day 1. The
dose of S-1 was escalated as follows: level 1, 30 mg/m2; level 2,
40 mg/m2; level 3, 45 mg/m2; level 4, 50 mg/m2. S-1 was adminis-
tered orally twice a day on days 1–14. Each cycle was repeated
every 21 days. DLTs were evaluated during the first two cycles
of treatment.
Findings: 19 patients were enrolled: 13 patients in the dose-
escalation phase and six patients in the extension at the recom-
mended dose. The median age was 53 years (range, 40–71 years).
At dose level 2, one DLToccured among six patients (grade 4 neu-
tropenia lasting more than 5 days), and at dose level 3, two DLTs
were observed among four patients (grade 3 diarrhoea and nau-
sea). Therefore, dose level 2 was determined to be the recom-
mended dose. Cumulative (all cycles) grade 3–4 toxicity included
neutropenia (58%), leucopenia (32%), thrombocytopenia (11%),
diarrhoea (11%), and nausea (5%). Of 13 patients with measurable
lesions, eight achieved a partial response and three had stable
disease, and the objective response rate was 62% (95% CI 36–
88%). Median progression-free survival was 6.5 months (4.7–8.2).
Interpretation The recommended dose of the EOS regimen in
patients with previously untreated AGC was epirubicin 50 mg/
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m2 and oxaliplatin 130 mg/m2 on day 1, and S-1 40 mg/m2 twice a
day on days 1–14 of every 21-day cycle. This regimen seems to
have promising preliminary activity.
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P39 A20 BINDING AND INHIBITOR OF NF-KAPPAB (ABIN-1) – A
POTENTIAL MARKER FOR SURVIVAL IN EARLY STAGE NON-
SMALL-CELL LUNG CANCER AFTER LUNG RESECTION
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Hospital, Central South University, Changsha, Hunan, China
Background: Currently, the role of A20 binding and inhibitor of
NF-kappaB (ABIN-1) in the development of non-small-cell lung
cancer remains unknown. This retrospective study investigated
expression of ABIN-1 and the association with prognosis in
patients with NSCLC after lung resection.
Methods: Quantitative real-time reverse transcriptase (RT)-PCR,
andWestern blot analyseswere used to detect expression of ABIN-
1 in 30 samples of NSCLC tissue and paracarcinomatous lung tis-
sue (PCLT), and in four samples of normal lung tissue. In addition,
immunohistochemical analysis was done for 80 NSCLC speci-
mens, and follow-up data from these patients were reviewed.
Findings: Both mRNA and protein expression of ABIN-1 were
significantly raised in NSCLC tissues compared with normal lung
tissues. Patients with NSCLC who had high ABIN-1 expression
had shorter overall survival than patients who had low ABIN-1
expression.
Interpretation: The current data revealed that increased expres-
sion of ABIN-1 was correlated with survival in patients with
NSCLC, indicating that ABIN-1 is a novel prognostic marker for
NSCLC.
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Background: Transitional-cell carcinoma (TCC) of the urinary
bladder is reported as the eighth most common malignancy and
the fourth most common among men in Pakistan. This study
aimed to assess the clinicopathological pattern, p53 status, and
stage distribution of TCC, and to classify bladder carcinomas pre-
senting among the population of central Punjab, including factory
workers, according to the revised WHO/ISUP criteria.
Methods: 145 patients, including 52 factory workers (mean age
35.2 years), with newly diagnosed operable primary bladder car-
cinomas who underwent cystoscopy-associated transurethral
resection of bladder tumours from January, 2004, to July, 2006,
were included. Relevant clinical and laboratory data of these
patients, including age, sex, tumour location, and type of surgi-
cal procedure, were recorded in separate proformas. After confir-
mation of the diagnosis, the tumours were graded separately for
each group – first, according to WHO Classification 1972 as pap-
illoma, TCC grade I, II, and III, and later, according to WHO/ISUP
Consensus Classification 1998 as papilloma, papillary neoplasm
of low malignant potential (PNLMP), low-grade papillary carci-
noma (LGPC), and high-grade papillary carcinoma (HGPC).
Tumour staging was done according to TNM criteria of the
American Joint Commission on Cancer. All tissues were also
subjected to immunohistochemistry (IHC) with monoclonal
anti-P53 antibody. Patients were followed up for 3 years, from
hospital records until July, 2010. Data were entered and analysed
using SPSS 17.0.
Findings: About 80% of patients were men and 20% were
women (the male-to-female ratio was 5.3:1). Clinical history was
similar for both sexes, with most patients (74%) presenting with
haematuria with or without altered urinary habits. WHO grading
revealed 35.9% grade I, 25.4% grade II, and 38.6% of tumours as
grade III. ISUP classification revealed 19.2% PNULMP, 23.6% LGPC,
39.4% HGPC, 9.6% non-papillary urothelial carcinomas (NPUC),
and 7.9% as carcinoma in situ (CIS). Tumour staging depicted an
overall 11.5% of tumours with stage Ta and 31.5% with stage T3-
4. Among 71% invasive carcinomas, 16% were low-grade and
84% were high-grade carcinomas. Immunohistochemical staining
of histological tissue sections of 73% of CIS and 84.23% of TCCs
were p53 positive. 10.7% of grade I, 44.9% of grade II, and 92.1%
of grade III tumours were positive for p53. There were signifi-
cantly more p53-positive cases seen in grade II–III tumours than
in grade I tumours (p = 0.0036). Similarly, stage T2–T4 tumours
stained more frequently and stronger than stage T1 tumours
(p = 0.021). No significant association between p53 status and
post-operative prognosis was observed in the 3 years of follow-
up (p = 2.131).
Interpretation: Prolonged follow-up of patients with bladder
cancer may indicate an unfavourable prognostic factor linked to
histopathological findings, and the presence of p53 mutation,
which may also indicate development of aggressive growth char-
acteristics in TCCs.
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METASTATIC PRESENTATION IN NON-SMALL-CELL LUNG
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